An Open-Label, Multicenter, Phase 1 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Intravenous Doses of Inhibrx rhAAT-Fc (INBRX-101) in Adults with Alpha-1 Antitrypsin Deficiency (AATD)

Recruiting
18 years - 70 years
All
1 Location

Brief description of study

The purpose of the study is to assess safety and tolerability of a Phase I drug, INBRX-101 in patients with alpha-1 antitrypsin deficiency (AATD).

Detailed description of study

Here at IU Health, we are recruiting for clinical trial to study the effects of a new drug on Alpha-1 Antitrypsin Deficiency (AATD).  All study procedures will take place at University Hospital at no cost to you.  You will be compensated for your time and effort.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Alpha-1 Antitrypsin Deficiency (AATD)
  • Age: 18 years - 70 years
  • Gender: All

Inclusion Criteria

AATD diagnosis, willing to undergo 2 bronchoscopies

Non-smoker

Willing to hold current AATD treatment until study ends (about 5 months).

Updated on 04 Aug 2024. Study ID: 1902734320

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Zip Code
Please provide your 5-digit zip code
0 0 /250
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team